<DOC>
	<DOCNO>NCT00056251</DOCNO>
	<brief_summary>Patients interstitial cystitis meet eligibility requirement randomize one four treatment arm ( 3 RTX , Placebo ) . Study drug administer single instillation within urinary bladder . Study duration 12 week .</brief_summary>
	<brief_title>Interstitial Cystitis</brief_title>
	<detailed_description>RATIONALE : Topical resiniferatoxin ( RTX ) administrate bladder may effective decreasing symptom associate interstitial cystitis action pain sensing neuron . PURPOSE : Randomized , double-blind , placebo-controlled , Phase 2 trial determine safety efficacy RTX patient interstitial cystitis .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>≥ 18 year age . Have IC meet disease diagnostic criterion define history following : Cystoscopy/hydrodistension diagnosis IC confirm finding Hunner ’ ulcer glomerulation Symptoms bladder pain urinary urgency least 6 month Urinary frequency awake least 8 time day awake Nocturia least twice night Symptoms significantly relieve antimicrobial agent , anticholinergic drug , antispasmodic Have IC judgment investigator stable previous 30 day Have ICrelated pain despite current therapy , define score 4 great [ ( scale 0 ( none ) 9 ( severe ) ] average past month confirm void diary collect Visit 2 Have least one voided volume ≥ 75 cc 24 hour period , confirm void diary collect Visit 2 Patients childbearing potential must agree use acceptable form contraception ( oral contraceptive , intrauterine device double barrier method ) Visit 1 Visit 6 Provide sign informed consent Currently pregnant breastfeed Presence ulcer pretreatment cystoscopy Intravesical therapy bladder hydrodistention within previous 60 day Initiation pentosan polysulfate sodium ( Elmiron® ) within previous 16 week Use fentanyl patch , morphine sulfate , methadone B &amp; O supprettes within previous 30 day . Previous augmentation cystoplasty , cystectomy cystolysis , neurectomy ( i.e. , hypogastric nerve plexus ablation ) implant peripheral nerve stimulator affect bladder function History ureteral reflux . Patients history childhood urinary tract infection , recurrent urinary tract infection adult ( define &gt; 3 culture document episode within previous 12 month ) , pyelonephritis time must cystourethogram rule ureteral reflux . Evidence renal impairment ( creatinine &gt; 2 time upper limit normal Visit 1 ) , hepatic impairment ( AST ALT &gt; 3 time upper limit normal Visit 1 ) , clinically significant cardiovascular , respiratory , psychiatric diseases Any condition judgment investigator would interfere patient ’ ability provide inform consent , comply study instruction , place patient increase risk , might confound interpretation study result Treatment drug medical device receive regulatory approval within previous 30 day Investigators , study staff immediate family . Immediate family define current spouse , parent , natural legally adopt child ( include stepchild living investigator ’ household ) , grandparent , grandchild . Previously complete withdrawn study Urinary tract prostatic infection within past 3 month study entry Active genital herpes vaginitis Urethral diverticulum Uterine , cervical , vaginal , urethral cancer within past 5 year study entry History cyclophosphamide chemical cystitis , urinary tuberculosis radiation cystitis History bladder tumor ( benign malignant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2004</verification_date>
	<keyword>Interstitial Cystitis</keyword>
	<keyword>Bladder</keyword>
</DOC>